Nello Mainolfi - 03 Mar 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
03 Mar 2025
Net transactions value
$0
Form type
4
Filing time
03 Mar 2025, 18:30:03 UTC
Previous filing
13 Jan 2025
Next filing
03 Jun 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +365,000 $0.000000 365,000 03 Mar 2025 Common Stock 365,000 $30.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 3, 2025, subject to the reporting person's continued employment through each vesting date.